Loading stock data…
Ascendis Pharma A/S (ASND)
$270.56-0.56 (-0.21%)
Pre-Market$263.06-7.50 (-2.77%)· Last close Sep 4
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ascendis Pharma A/S in the Healthcare sector is trading at $270.56 with a market capitalization of $13.8B. Wall Street consensus targets $314.51 (20 analysts), implying a +16.2% move over the next 12 months. The stock is currently near its 52-week high of $282.15, remaining 16.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +16.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $246.60M↓ | $247.50M↑ | $213.63M↑ | $158.04M↑ | $100.95M |
| Gross Profit | $229.09M↑ | $223.90M↑ | $191.28M↑ | $126.60M↑ | $83.44M |
| Operating Income | $24.81M↑ | $6.44M↓ | $11.00M↑ | -$52.95M↑ | -$104.21M |
| Net Income | $629.34M↑ | -$33.56M↑ | -$60.99M↓ | -$38.85M↑ | -$94.63M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.85B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.44
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
101.63%
Volume
Today's trading volume
723,515
Recent News
BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has converted a global patent dispute with Ascendis Pharma A/S (NASDAQ:ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment approved to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will receive royalties equal to 20% of U.S. Yuviwel net […]
Ascendis Pharma (ASND) Reimbursement Win Puts Its Fair Value Narrative Back In Focus
Ascendis Pharma (NasdaqGS:ASND) drew fresh investor attention after Canada’s Drug Agency recommended conditional public reimbursement for Yorvipath, its parathyroid hormone replacement therapy for eligible adults with chronic hypoparathyroidism. Ascendis Pharma’s recent news flow, including the Canadian reimbursement recommendation for Yorvipath and the late August global settlement with BioMarin over Yuviwel, has arrived alongside strong price momentum, with a 90 day share price return of...
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing
Ascendis Pharma (NasdaqGS:ASND) reached a global settlement and licensing agreement with BioMarin Pharmaceutical that resolves worldwide patent disputes related to Yuviwel. The deal grants Ascendis Pharma a license to continue commercializing Yuviwel and related products across global markets. Ascendis Pharma also received a positive reimbursement recommendation in Canada for Yorvipath for adults with chronic hypoparathyroidism. These legal and reimbursement outcomes affect Ascendis Pharma's...
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.
Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute
Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.